LAUREANO SIMON, Oncomatryx CEO, declares war on tumor microenvironment. “We envision a new era where cancer in general and invasive tumors in particular will be beaten with orchestrated combinations of precision
Published by Deia 2022 – 05 -23
Published by EXPANSIÓN 2022-03-08 Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.
Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards
12 Annual PEGS Europe Virtual Summit 2020 9 Nov – 12 Nov 2020 Myriam Fabre, PhD. (Oncomatryx R&D Director) will attend the virtual conference as a speaker on next Tuesday
ESMO 2018 Congress Munich, Germany – 19 Oct – 23 Oct 2018 Myriam Fabre, PhD. (Oncomatryx R&D Director) presents the poster: OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with
Oncomatryx will attend BIO EUROPE SPRING 2018, the essential appointment in biotechnology BIO EUROPE SPRING 2018 March 12-14, 2018 Amsterdam, The Netherlands https://ebdgroup.knect365.com/bioeurope- If you are also attending this event and you would like
Oncomatryx will attend BIO 2017, the Global Event for Biotechnology.
ENTURE SUMMIT WEST 2017 February 28 – March 1 2017 Mountain View, CA USA David Raksin, our Business Development Director will be a Presenting role as a Top Innovator in
Antibody Drug Conjugates Against Tumor Stroma: The Beginning of The End? by Mirella Zulueta, Business Development Director at Oncomatryx The potential of a technology trigger Despite many research breakthroughs
